Loading company…
Morebio develops peptide-based biopharmaceuticals, cell products, cosmetics and contract development services.
Founded in 2008 and based in Wuhan, China, Morebio researches, develops and produces peptide-based biopharmaceuticals. Its work includes Semaglutide and other gene-engineered products, cell products, functional cosmetics and CDMO services for pharmaceutical companies and research institutions. In March 2025, it received venture funding from Jinlan Investment Management to advance products and explore expansion into North America and Europe.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in